Detalles de la búsqueda
1.
Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.
Future Oncol
; 17(24): 3137-3150, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34008425
2.
Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis.
Future Oncol
; 15(13): 1481-1491, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30839234
3.
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 18(11): 1454-1466, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28958502
4.
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
J Clin Oncol
; 36(22): 2244-2250, 2018 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29864379
5.
Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.
Lung Cancer
; 112: 195-199, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29191595
6.
Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).
Lung Cancer
; 106: 76-82, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28285698
7.
A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
Cancer Chemother Pharmacol
; 71(5): 1273-85, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23468081
8.
Phase I study of sequential administration of topotecan and 5-fluorouracil in patients with advanced malignancies.
Cancer Invest
; 20(5-6): 644-50, 2002.
Artículo
en Inglés
| MEDLINE | ID: mdl-12197219
Resultados
1 -
8
de 8
1
Próxima >
>>